Hospital del Mar Research Institute
Barcelona, Catalonia, 08003, Spain
Location status: Recruiting
NCT Number: NCT06965972
Background Frailty has become a major problem for the health system, but also a window of opportunity to fight against disability through preventive strategies focused on the detection and treatment of frailty in all settings. However, no systematic strategies of screening and early detection are available in clinical settings. This project aims to identify clinical and biological phenotypic clusters that drive through the different stages of frailty and to describe the underlying mechanisms of the trajectories leading to disability and the potential for treatment. Moreover, validation of Frailty Trait Scale 5 (FTS5) will be performed as an easy model to be implemented in primary care and hospital scope.
Methods/design A prospective population-based cohort will be stablished for frailty phenotyping (CohorFES). Creation of a CIBERFES Biobank where blood and urine samples from participants of CohortFES are stored for future researches. Demographic and clinical history data, anthropometric measurements, predimed questionnaire, peripheral blood biochemical variables and metabolomics were collected for each participant at baseline and every year until become frailty.
Using cluster partition models (k-means and hierarchical clustering) will group together individuals with similar deficits and characteristics (frailty phenotypes). Then, by using pre-established criteria (gap and silhouette), the proposed clustering solution (belonging to given clusters) will be evaluated. Further, investigators will assess, in a longitudinal fashion, the appearance and accumulation of deficits during the study period and identifying the clusters subgroups with more rapid progression. Results will be applied to establish and compare clusters and trajectories. Finally, frailty phenotypes and patient clusters will be correlated with health outcomes such as the use of health services (both primary and secondary care), hospital admissions, and mortality.
Discussion Information about clinical and biological phenotypic clusters that drive through the different stages of frailty can lead to identify potential targets that could improve the therapeutic management of these patients.
In summary, from a research perspective the project aims to better understanding of the interindividual variability in clinical events that lead to frailty, dependence and finally, to death.
Interested in participating?
Request Info65 year–120 year
All sexes
Observational
Barcelona, Catalonia, 08003, Spain
Location status: Recruiting
Frailty is one of the major challenges of the 21st Century, and a top priority for national and international organisms like the WHO (World Health Organization) or the European Parliament. This has put frailty as one of the top priorities in the biomedical research agenda of the European Commission. Frailty is constituted by a physiological state of increased vulnerability and impaired resilience to stressors (i.e. diseases, external agents, drugs tolerability and toxicity) due to the combined effect of the aging process and some chronic diseases which drives to a final stage of dependency and disability with a sharp impact in quality of life, health and social resources consumption, hospitalization and death.
It is well-known the relevance of frailty, its detection, and management since we are aware about their reversibility, the costs on the health systems, and its potential impact in clinical settings. In a clear contrast with the abundancy of data in non-clinical settings, there is a lack of strong data in the clinical setting where the prevalence of frailty is higher and where the risks for developing its most serious adverse consequences is more likely. There is hence an urgent need for a better screening and diagnosis of frailty, its trajectories and the determinants of these separate trajectories depending upon both the characteristics of frailty in each patient (associated or not with sarcopenia, or cognitive impairment or different clusters of chronic diseases).
While the different categories of the syndrome based on the severity of the observed deficits (robust, frail, pre-frail) are quite well defined and characterized from an epidemiological point of view, there is a scarcity of data on the functional pathways between these diagnostic categories (and, among them, disability), and this is especially true in clinical cohorts. This is really shocking considering that one of the most relevant factors, if not the first one, associated with a poor evolution of frailty is to experience an episode of hospitalization.
The overarching goal of this study is therefore, to identify the critical subgroups of subjects at risk of progression from robustness to prefrailty and frailty and from there to their late stages, and the pathways that mediate this trajectory amongst community-dwelling Spanish subjects.
Another important issue in this field would be to find an easy tool to identify frailty and factors which could be implemented in our full outpatients list. In addition to the more classical instruments to assess frailty, several groups currently members of CIBER on Frailty and Healthy Ageing (CIBERFES) developed an instrument that overcomes some of the problems raised by the more classical ones. The Frailty Trait Scale-FTS has shown a good predictive capacity for some outcomes in very old patients living in the community. More recently, and as part of an EU-funded project (FRAILTOOLS) we have found that the full version of FTS is able to detect frailty in some clinical settings (Acute Care Geriatric Unit, Geriatric Service outpatient office and Primary Care), with a good predictive capacity for adverse outcomes (death, incident disability, deterioration in SPPB, falls and hospitalization) at 6-12-18 months. However, the full version of FTS, composed of 12 items, takes around 15 minutes, making it unpractical in usual clinical conditions, where the time available by the physician or the nurse is lower. With this fact in mind, a shorter version of only 5 items (the so-called FTS 5) was developed.
This shorter version takes less time, but more interestingly, FTS 5 offers promising results based upon the sensitivity to detect small changes shown by the full FTS. Finally, the variables that compose the FTS5 (gait velocity, grip strength, BMI, PASE, and balance) can be incorporated into electronic instruments. This has been the case for the electronic frailty index (eFI), developed and validated in the British electronic records based on the Rockwood's frailty model that would allow to assess the frailty profile after to consider 36 items or deficits at the same moment of visit by primary care o hospital physician or the more recent Hospital Frailty Risk Score based on clinical diagnoses that is able to predict death but showing only a fair concordance with the Frailty Phenotype and the Frailty Index.
The use of easy electronic tools has been useful not only in hospital care but also in routine primary care practice. Moreover, it would be easier to measure the adverse outcomes, including falls, delirium, disability, care home admission, hospitalization and mortality as it has been recently shown.
Inside this conceptual framework and considering the scarce data available in clinical settings about frailty diagnosis, trajectories and prognosis, the main goal of this project is to stablish a clinical, real-life and prospective cohort (COHORFES) to identify clinical and biological phenotypic clusters that drive through the different stages of frailty and to identify the underlying mechanisms that finally will trigger the disability.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: Through study completion, an average of 5 years
Frailty measure
Time frame: Through study completion, an average of 5 years
Frailty measure
Time frame: Through study completion, an average of 5 years
Frailty measure
Time frame: Through study completion, an average of 5 years
Bone Mineral Density measured using a Dual-Energy X-Ray Analysis (DXA) device (Hologic Horizon Wi, Hologic®).
Time frame: Through study completion, an average of 5 years
Detection of anormal values of the following parameters (y/n):
These parameters are combined with the final outcome: abnormal biochemistry (y/n)
Time frame: baseline
Age in years
Time frame: baseline
Date (dd/mm/yyyy)
Time frame: baseline
sex (Male or Female)
Time frame: baseline
Living situation: Alone or accompanied
Time frame: baseline
Educational level: number of years in the school and college
Time frame: From baseline until the date of death from any cause, an average of 5 years
mortality during study follow-up (y/n)
Time frame: Through study completion, an average of 5 years
New condition diagnosis during follow-up (for ex. diagnosis of cancer, fracture, dementia, etc)
Time frame: Through study completion, an average of 5 years
treatments being taken by the patient
Time frame: Through study completion, an average of 5 years
number of different drugs being taken by the patient
Time frame: Through study completion, an average of 5 years
Loss of weight in the last year in grams
Time frame: Through study completion, an average of 5 years
Geriatric Depression Scale: 15 items (y/n) were combined to report GDS
Time frame: Through study completion, an average of 5 years
Barthel Index: measure of functional disability
Time frame: Through study completion, an average of 5 years
to assess independent living skills. It contains 8 items that are rated with a summary score from 0 (low functioning) to 8 (high functioning).
Time frame: Through study completion, an average of 5 years
test of 10 questions used to assess a person's cognitive status
Time frame: Through study completion, an average of 5 years
The adherence of participants to the Mediterranean diet will be assessed through the 14-item Mediterranean diet adherence screener (MEDAS) validated for the Spanish population in a phone interview with the participant
Time frame: Through study completion, an average of 5 years
number of medical care consultations
Time frame: Through study completion, an average of 5 years
Number of admissions in a Hospital
Time frame: Through study completion, an average of 5 years
Quantitative metabolomics approach applied to analyze plasma samples using liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS). It is defined as altered metaboloma (y/n)
Interested in participating?
Request InfoParc de Salut Mar
Other
Prospective Cohort for the Study of Phenotypic Clusters, Progression Paths and Outcomes of Frailty and Dependence: The Spanish CohorFES
Acronym: COHORFES
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07813702
Atrophy, Female Urogenital Diseases
Karabük, Merkez, Turkey (Türkiye)
View Trial DetailsNCT07345832
Atrophy, Fall Prevention in Healthy Aging
Hong Kong
View Trial DetailsNCT06611228
Aging, Frailty
Monza, Lumbardy, Italy
View Trial DetailsNCT05091645
Femoral Fractures, Fractures, Bone
Larissa, Greece
View Trial Details